Comparative analysis of gut microbiota in incident and prevalent peritoneal dialysis patients with peritoneal fibrosis, correlations with peritoneal equilibration test data in the peritoneal fibrosis cohort
- PMID: 39520210
- DOI: 10.1111/1744-9987.14226
Comparative analysis of gut microbiota in incident and prevalent peritoneal dialysis patients with peritoneal fibrosis, correlations with peritoneal equilibration test data in the peritoneal fibrosis cohort
Abstract
Introduction: The connection between peritoneal function and gut microbiota in peritoneal fibrosis (PF) patients remains uncertain.
Methods: Peritoneal equilibration test (PET) was employed to evaluate peritoneal function in patients with peritoneal fibrosis (PF). 16S rRNA sequencing was used to analyze the gut flora in incident peritoneal dialysis (PD) and PF groups, identifying differential microbial communities. Spearman's correlation analysis, conducted using SPSS 26.0, was employed to explore the microbial associations with PF.
Results: In the PF group, the PET showed a 4-h dialysate-to-plasma creatinine ratio (D/PCr) ratio of 0.62 ± 1.01 and a 4-h ultrafiltration (UF) volume of 41.73 ± 76.71 mL with a 2.5% glucose dwell. The alpha diversity between the PD and PF groups did not exhibit a significant difference. The PD and PF groups were predominantly composed of Firmicutes, Tenericutes, and Ignavibacteriae. Linear discriminant analysis effect size (LEfse) analysis indicates that the Firmicutes, Lactobacillales, and Bacilli were significantly enriched in the PD group, whereas Lachnospiraceae, Phenylobacterium, and Caulobacteraceae were enriched among the PF group. The functional prediction of gut microbiota genes revealed variations in metabolic pathways related to lipid transport, energy metabolism, and post-translational protein modifications between the two cohorts. In the PF group, Ignavibacteriae and Bdellovibrio correlated positively with the 4-h D/PCr ratio (p <0.05), while Prevotella negatively correlated with the 4-h UF from 2.5% glucose dwell (p <0.05).
Conclusion: The intestinal microbiota of patients newly initiated on peritoneal dialysis significantly differs from that of those with long-term peritoneal dialysis complicated by peritoneal fibrosis, with the latter's peritoneal function potentially linked to Prevotella, Ignavibacteriae, and Bdellovibrio.
Keywords: 16S rRNA sequencing; end‐stage kidney disease; gut microbiota; peritoneal dialysis; peritoneal fibrosis.
© 2024 International Society for Apheresis and Japanese Society for Apheresis.
Similar articles
-
Gender impact on baseline peritoneal transport properties in incident peritoneal dialysis patients.Int Urol Nephrol. 2019 Nov;51(11):2055-2061. doi: 10.1007/s11255-019-02237-8. Epub 2019 Jul 22. Int Urol Nephrol. 2019. PMID: 31332698
-
BMSC-derived Exosomes Ameliorate Peritoneal Dialysis-associated Peritoneal Fibrosis via the Mir-27a-3p/TP53 Pathway.Curr Med Sci. 2024 Apr;44(2):333-345. doi: 10.1007/s11596-024-2853-7. Epub 2024 Apr 16. Curr Med Sci. 2024. PMID: 38622424
-
Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution?Perit Dial Int. 2001 Mar-Apr;21(2):219-24. Perit Dial Int. 2001. PMID: 11330572
-
Icodextrin Versus Glucose Solutions for the Once-Daily Long Dwell in Peritoneal Dialysis: An Enriched Systematic Review and Meta-analysis of Randomized Controlled Trials.Am J Kidney Dis. 2020 Jun;75(6):830-846. doi: 10.1053/j.ajkd.2019.10.004. Epub 2020 Feb 4. Am J Kidney Dis. 2020. PMID: 32033860
-
Use of intraperitoneal pressure, ultrafiltration and purification dwell times for individual peritoneal dialysis prescription in children.Clin Nephrol. 1996 Jul;46(1):14-6. Clin Nephrol. 1996. PMID: 8832143 Review.
Cited by
-
Analysis of cullin family genes in rectal adenocarcinoma: expression, prognostic significance, and therapeutic implications.Am J Transl Res. 2025 May 15;17(5):3842-3861. doi: 10.62347/UNVS8140. eCollection 2025. Am J Transl Res. 2025. PMID: 40535676 Free PMC article.
-
Alcohol-induced bone loss driven by dysregulated spatial distribution of gut microbiota and PGD2-IL17 pathway-mediated osteoclast activation.Front Microbiol. 2025 May 15;16:1551028. doi: 10.3389/fmicb.2025.1551028. eCollection 2025. Front Microbiol. 2025. PMID: 40443995 Free PMC article.
-
Exosomal miRNAs as biomarkers and therapeutic targets in silicosis-related lung fibrosis.Mol Biol Rep. 2025 Jun 12;52(1):585. doi: 10.1007/s11033-025-10687-w. Mol Biol Rep. 2025. PMID: 40504442 Free PMC article. Review.
-
Exploring TGF-β signaling in benign prostatic hyperplasia: from cellular senescence to fibrosis and therapeutic implications.Biogerontology. 2025 Mar 30;26(2):79. doi: 10.1007/s10522-025-10226-x. Biogerontology. 2025. PMID: 40159577 Review.
-
Personalized colorectal cancer risk assessment through explainable AI and Gut microbiome profiling.Gut Microbes. 2025 Dec;17(1):2543124. doi: 10.1080/19490976.2025.2543124. Epub 2025 Aug 4. Gut Microbes. 2025. PMID: 40760681 Free PMC article.
References
REFERENCES
-
- Ene‐Iordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN‐KDDC): a cross‐sectional study. Lancet Glob Health. 2016;4(5):e307–e319.
-
- Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China: a cross‐sectional survey. Lancet. 2012;379(9818):815–822.
-
- Project group of “White paper on the status of peritoneal dialysis management in China”. White paper on the current status of peritoneal dialysis management in China. Chin J Nephrol. 2022;38(12):1076–1104.
-
- Teitelbaum I. Peritoneal dialysis. N Engl J Med. 2021;385(19):1786–1795.
-
- Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end‐stage kidney disease: a systematic review. Lancet. 2015;385(9981):1975–1982.
Grants and funding
- 81903684/National Natural Science Foundation of China
- 2019YX019/Hospital Pharmacy Research Foundation of Changzhou Siyao Hospital and Nanjing Pharmaceutical Association
- 021414380498/Fundamental Research Funds for the Central Universities
- JY202206/Jiangsu Research Hospital Association for Precision Medication
- Foundation of Nanjing Medical Center for Clinical Pharmacy
LinkOut - more resources
Full Text Sources